Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Linagliptin (Trajenta®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0112. 2012 Authors' conclusions Linagliptin (Trajenta®) is not recommended for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:
Monotherapy:
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
Combination therapy:
in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control
The evidence presented in the submission was insufficiently robust for AWMSG to recommend its use. Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Purines; Quinazolines Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000339 Date abstract record published 08/08/2012 |